208 related articles for article (PubMed ID: 15501347)
1. [Effect of smoking on the effectiveness of antimalarial drugs for cutaneous lesions of patients with lupus: assessment in a prospective study].
Lardet D; Martin S; Truchetet F; Cuny JF; Virion JM; Schmutz JL
Rev Med Interne; 2004 Nov; 25(11):786-91. PubMed ID: 15501347
[TBL] [Abstract][Full Text] [Related]
2. Lupus erythematosus tumidus: response to antimalarial treatment in 36 patients with emphasis on smoking.
Kreuter A; Gaifullina R; Tigges C; Kirschke J; Altmeyer P; Gambichler T
Arch Dermatol; 2009 Mar; 145(3):244-8. PubMed ID: 19289751
[TBL] [Abstract][Full Text] [Related]
3. Hydroxychloroquine and smoking in patients with cutaneous lupus erythematosus.
Ezra N; Jorizzo J
Clin Exp Dermatol; 2012 Jun; 37(4):327-34. PubMed ID: 22582908
[TBL] [Abstract][Full Text] [Related]
4. Optimal use of antimalarials in treating cutaneous lupus erythematosus.
Wozniacka A; McCauliffe DP
Am J Clin Dermatol; 2005; 6(1):1-11. PubMed ID: 15675885
[TBL] [Abstract][Full Text] [Related]
5. Combined mepacrine-hydroxychloroquine treatment in patients with systemic lupus erythematosus and refractory cutaneous and articular activity.
Ugarte A; Porta S; Ríos R; Martinez-Zapico A; Ortego-Centeno N; Agesta N; Ruiz-Irastorza G
Lupus; 2018 Sep; 27(10):1718-1722. PubMed ID: 29635998
[TBL] [Abstract][Full Text] [Related]
6. Low blood concentration of hydroxychloroquine in patients with refractory cutaneous lupus erythematosus: a French multicenter prospective study.
Francès C; Cosnes A; Duhaut P; Zahr N; Soutou B; Ingen-Housz-Oro S; Bessis D; Chevrant-Breton J; Cordel N; Lipsker D; Costedoat-Chalumeau N
Arch Dermatol; 2012 Apr; 148(4):479-84. PubMed ID: 22508872
[TBL] [Abstract][Full Text] [Related]
7. Toll-like receptor-9 signaling and decreased efficacy of antimalarial drugs in smokers with cutaneous lupus erythematosus.
Kwatra SG
J Am Acad Dermatol; 2015 Aug; 73(2):e79. PubMed ID: 26184008
[No Abstract] [Full Text] [Related]
8. The association of the two antimalarials chloroquine and quinacrine for treatment-resistant chronic and subacute cutaneous lupus erythematosus.
Feldmann R; Salomon D; Saurat JH
Dermatology; 1994; 189(4):425-7. PubMed ID: 7873836
[TBL] [Abstract][Full Text] [Related]
9. Patients with cutaneous lupus erythematosus who smoke are less responsive to antimalarial treatment.
Jewell ML; McCauliffe DP
J Am Acad Dermatol; 2000 Jun; 42(6):983-7. PubMed ID: 10827400
[TBL] [Abstract][Full Text] [Related]
10. Management of antimalarial-refractory cutaneous lupus erythematosus.
Callen JP
Lupus; 1997; 6(2):203-8. PubMed ID: 9061669
[No Abstract] [Full Text] [Related]
11. Influence of smoking on the efficacy of antimalarials in cutaneous lupus: a meta-analysis of the literature.
Chasset F; Francès C; Barete S; Amoura Z; Arnaud L
J Am Acad Dermatol; 2015 Apr; 72(4):634-9. PubMed ID: 25648824
[TBL] [Abstract][Full Text] [Related]
12. Cutaneous lupus erythematosus: factors related to cutaneous activity and damage in a cohort of 260 patients from A Coruña, Spain.
Arévalo-Bermúdez MDP; Paradela S; Balboa-Barreiro V; Fonseca E
Lupus; 2020 Aug; 29(9):1021-1030. PubMed ID: 32539659
[TBL] [Abstract][Full Text] [Related]
13. Impact of smoking in cutaneous lupus erythematosus.
Piette EW; Foering KP; Chang AY; Okawa J; Ten Have TR; Feng R; Werth VP
Arch Dermatol; 2012 Mar; 148(3):317-22. PubMed ID: 22105815
[TBL] [Abstract][Full Text] [Related]
14. Smoking enhances Toll-like receptor-9 responsiveness and type I interferon production in plasmacytoid dendritic cells in patients with cutaneous lupus erythematosus.
Chasset F; Francès C; Arnaud L
J Am Acad Dermatol; 2015 Aug; 73(2):e81. PubMed ID: 26184009
[No Abstract] [Full Text] [Related]
15. Changing antimalarial agents after inefficacy or intolerance in patients with cutaneous lupus erythematosus: A multicenter observational study.
Chasset F; Arnaud L; Jachiet M; Monfort JB; Bouaziz JD; Cordoliani F; Bagot M; Barbaud A; Francès C
J Am Acad Dermatol; 2018 Jan; 78(1):107-114.e1. PubMed ID: 29061479
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and comparison of antimalarials in cutaneous lupus erythematosus subtypes: a systematic review and meta-analysis.
Chasset F; Bouaziz JD; Costedoat-Chalumeau N; Francès C; Arnaud L
Br J Dermatol; 2017 Jul; 177(1):188-196. PubMed ID: 28112801
[TBL] [Abstract][Full Text] [Related]
17. Response to antimalarial agents in cutaneous lupus erythematosus: a prospective analysis.
Chang AY; Piette EW; Foering KP; Tenhave TR; Okawa J; Werth VP
Arch Dermatol; 2011 Nov; 147(11):1261-7. PubMed ID: 21768444
[TBL] [Abstract][Full Text] [Related]
18. Antimalarial drugs, systemic lupus erythematosus and pregnancy.
Parke AL
J Rheumatol; 1988 Apr; 15(4):607-10. PubMed ID: 3397970
[TBL] [Abstract][Full Text] [Related]
19. Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Mittal L; Zhang L; Feng R; Werth VP
J Am Acad Dermatol; 2018 Jan; 78(1):100-106.e1. PubMed ID: 28989103
[TBL] [Abstract][Full Text] [Related]
20. Previous antimalarial therapy in patients diagnosed with lupus nephritis: influence on outcomes and survival.
Sisó A; Ramos-Casals M; Bové A; Brito-Zerón P; Soria N; Muñoz S; Testi A; Plaza J; Sentís J; Coca A
Lupus; 2008 Apr; 17(4):281-8. PubMed ID: 18413408
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
